New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
05:29 EDTPLXProtalix announces first patient treated in Phase I/II study of Fabry patients
Protalix BioTherapeutics announced that the first patient has been treated in the company's phase I/II clinical trial of Fabry patients with PRX-102. PRX-102 is the company's proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme in development as a long-term enzyme replacement therapy for the treatment of Fabry disease.
News For PLX From The Last 14 Days
Check below for free stories on PLX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
13:47 EDTPLXBio-Cell reduces stake in Protalix to 1.61% from 10.7%
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use